Mark A. Socinski, MD, discusses the evolving paradigm of targeted therapy in lung cancer.
Mark A. Socinski
Advertisement
Articles by Mark A. Socinski
Mark A. Socinski, MD, executive medical director of the Florida Hospital Cancer Institute, discusses challenges facing immunotherapy combinations in patients with non–small cell lung cancer (NSCLC).
Advertisement
Latest Updated Articles
Dr. Socinski on the Evolving Paradigm of Targeted Therapy in Lung CancerPublished: May 18th 2021 | Updated:
Dr. Socinski on Challenges Facing Immunotherapy CombinationsPublished: February 3rd 2017 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approval Tees Up T-DXd Plus Pertuzumab as a New SOC in HER2+ Breast Cancer
2
Iberdomide Plus Daratumumab/Dexamethasone Displays High Response Rates in NDMM
3
FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC
4
NALIRIFOX and FOLFIRINOX Facilitate Personalized Treatment in Metastatic Pancreatic Cancer
5